

## Stabilization of Paclitaxel Composition

Paclitaxel, better known as *Taxol*, is a blockbuster *ex-patent* oncology drug. It is used in treatment of a variety of cancers and involves special delivery methods. Paclitaxel is a natural product originally extracted from the Pacific Yew but, as research continued over a number of years, it became available by semi-synthetic routes and by biosynthesis, as well as, in quantities suitable for research, by total synthesis.



The client patent in this case related to a composition specially formulated for greater drug stability. It was opposed in the European Patent Office (“EPO”) by multiple active opponents. The patent was revoked and an appeal filed. The client then sold the relevant business unit. In the hands of new legal representation, the appeal failed, as did separate attempts to secure patent protection.

[Client Appeal Submission](#)